An interventional study of Habit Reversal Training in Tics, Tourette Disorder and Tourette Syndrome in Children, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by University of Utah · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Tics with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Tics · United States.
Among the 48 studies in Tics with a site in United States, this one is the 34th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 21 with no phase, and was the 45th registered.
65 studies on the registry are indexed under Tics; 11 are open to participants now.
Browse Tics studies →8 of the 48 studies in Tics with a site in United States are open now. Recruiting first, the newest first:
National Institute of Neurological Disorders and Stroke (NINDS) · Sites in United States
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 15–35
University of Minnesota · Sites in United States
Ages 12–21
University of Utah · Sites in United States
Ages 8–12
University of California, Los Angeles · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Tics studies recruiting now, none set no upper age limit and 8 stop at 75 or younger; 6 take children under 18; none take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 4
First in 1997; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6 is below the median of 34 across 51 interventional studies indexed under Tics.
Median enrollment 31 across the 37 interventional studies, 43 across the 11 observational. Of the 37 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 48 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 5 studies filed under Tics — fewer than ten, so there is no comparison to draw.
1 of the studies in Tics with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 48 studies in Tics with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim of this study is to learn more about premonitory urges (PU) when using Habit Reversal Training (HRT) to treat tics.
The main focus of this study is to investigate if and when PU change during tic treatment sessions and between tic treatment sessions.
Participants will:
Current research has shown that although tics can be effectively reduced with short-term suppression strategies or habit reversal training (HRT), it remains unclear whether improvement in tic symptoms is accompanied by a reduction in premonitory urges (PUs). Premonitory urges are uncomfortable premonitory sensations that signal a tic is about to occur. Most individuals describe these premonitory sensations as an itch, pressure, energy, or other uncomfortable or "not just right" sensation that is usually localized to the area of the body in which the tic occurs. Furthermore, most individuals report that their PUs increase when tics are suppressed and are reduced or eliminated, albeit temporarily, after the tic is executed. Because the execution of tics reduces aversive PUs, it has been hypothesized that they are strengthened, shaped, and maintained, at least in part, by automatic negative reinforcement. Further investigation into the PU-tic association during treatment is needed. A better understanding of how PUs fluctuate during HRT (both within and between sessions) will potentially provide further insight into its underlying mechanism(s). A better understanding of how PUs fluctuate during HRT (both within and between sessions) will potentially provide further insight into its underlying mechanism(s). Specifically, if tics reduce but PU do not reduce when within and between HRT sessions, such findings would cast doubt on the role of habituation and spur the investigation of alternative hypotheses. The primary aim of this study is to contribute to the current literature on the model of tic maintenance and reduction and the PU-tic association by investigating individual PU severity fluctuations within and between sessions when using HRT to treat tics. Specifically, the study will examine whether subjective ratings of PUs decrease within and between sessions following HRT, as would be expected from the habituation hypothesis.
The primary aim of this study is to contribute to the current literature on the model of tic maintenance and reduction and the PU-tic association by investigating individual PU severity fluctuations within and between sessions when using HRT to treat tics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who meet criteria for a diagnosis of a TD will be recruited to participate in this study. Participants will be eligible for the study if they
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 therapist-guided sessions of habit reversal training (1 hour each) for 3 separate identified tics. Participant will also participate in 5 practice sessions per week (approximately 30 minutes sessions each; over the course of 3 weeks) in which participants will practice the skills learned in session with a study team member)
Behavioral: Habit Reversal Training
Participants learn to identify when their tics occur and then learn a competing response to engage in instead of the 3 identified tics and then practice competing responses learned in session during the practice sessions throughout the week.
Premonitory Urge (PU) Severity as measured by the urge thermometer
Premonitory urge (PU) severity is an subjective measure of PU ratings while participants are implementing their competing response during study treatment sessions or practice sessions. The Urge Thermometer is an adapted version of the "feelings thermometer" from the Anxiety Disorders Interview Schedule for DSM-IV. It is a 9-point rating scale, ranging from 0 to 8 with higher scores indicating stronger urge experiences, designed to efficiently collect the patients' subjective rating of the severity/intensity of their urge.
Time frame: PU severity will be measured during a 10 minute baseline observation; approximately 15 minutes or until 5 CR initiations have occurred, whichever is longer during each of the 3 HRT sessions and 15 practice sessions; during the 15 minute post assessment
Tic Change as measured by tic counts
Coding for tics will utilize 10-second partial interval coding in which the presence or absence of each target tic is recorded as present or absent in each 10-s interval. Tic rate will be calculated by dividing the number of intervals in which each target tic is present by the total number of intervals and multiplying this number by 100%. Ten-second partial interval coding has been shown to provide a reliable and valid measure of tics over observation periods of 5 minutes or longer (Himle et al., 2006).
Time frame: Tics will be counted during a 10 minute baseline observation; approximately 15 minutes or until 5 CR initiations have occurred, whichever is longer during each of the 3 HRT sessions and 15 practice sessions; during the 15 minute post assessment
Participant scores on Treatment Expectancy and Acceptability Questionnaire at baseline
At the baseline assessment, participants will be asked to rate how much they believe in the treatment on a 5-point scale, and how much they think their tics will improve on a 5-point scale with additional questions from the Credibility/Expectancy Questionnaire (Devilly \& Borkovec, 2000). Scores can range from 3 to 15. Participants will also be asked to rate treatment acceptability at pre-treatment (including questions about the acceptability, ethicality, effectiveness, and potential negative side effects of the treatment). Questions are rated on a 1 to 7 scale, with lower scores representing more negative impressions and reactions to the proposed treatment. Scores can be totaled ranging from 6 to 42.
Time frame: Given at baseline (first study visit)
Patient scores on Satisfaction with Therapy and Therapist Scale- Revised (STTS-R) post treatment
The STTS is a commonly used 13-item self-report measure that assesses patients' satisfaction with their therapist and the treatment that they received. Each item is rated on a 5-point Likert-type scale with higher scores indicating greater overall satisfaction with treatment and the therapist. Scores range from 15 to 65.
Time frame: Given at post assessment (final study visit) approximately 5 weeks from study initiation
Plan to share: Yes — Individual participant data that underlie results in any publication(s) may be provided to qualified researchers. All data shared will be coded with no identifying information included. Approval of the request by the study primary investigator and execution of all applicable data sharing agreements are prerequisites to the sharing of data with the requesting party.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Starting 6 months after publication.
Access criteria: Qualified researchers are those considered to have academic interests in tic disorders and related conditions, expertise in the scoring and interpretation of the outcome measures administered, and a reasonable and scientifically-sound justification for obtaining participant data.
Started Feb 2025 (actual). Primary completion is estimated for Jul 2025, 5 months after the start.
Of 22 interventional studies with no phase under Tics, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 43. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.